Prozorovskiĭ V B, Chepur S V, Vorob'ev-Desiatovskiĭ N V, Panov P B
Research Institute of Military Medicine, Russian Federation, St. Petersburg, Russia.
Eksp Klin Farmakol. 1998 Sep-Oct;61(5):46-9.
The results of studying the pharmacokinetics of aminostigmine, a new reversible cholinesterase inhibitor produced in Russia, are discussed. Tissue radioactivity after intragastric administration of a toxic dose of aminostigmine was quite quickly absorbed from the intestinal lumen. The half-life period of aminostigmine exceeded considerably that of earlier studied carbamates and correlated with the clinical manifestations of the drug effects. This confirms that the use of aminostigmine in the treatment of neurologic and somatic diseases is preferable.
讨论了对俄罗斯生产的一种新型可逆性胆碱酯酶抑制剂氨基新斯的明的药代动力学研究结果。经胃给予毒性剂量的氨基新斯的明后，组织放射性很快从肠腔吸收。氨基新斯的明的半衰期大大超过了早期研究的氨基甲酸盐类，并且与药物作用的临床表现相关。这证实了在治疗神经和躯体疾病中使用氨基新斯的明更可取。
